[go: up one dir, main page]

FI914796L - Omaettade hydroxialkylkinolinsyror som leukotrienantagonister. - Google Patents

Omaettade hydroxialkylkinolinsyror som leukotrienantagonister. Download PDF

Info

Publication number
FI914796L
FI914796L FI914796A FI914796A FI914796L FI 914796 L FI914796 L FI 914796L FI 914796 A FI914796 A FI 914796A FI 914796 A FI914796 A FI 914796A FI 914796 L FI914796 L FI 914796L
Authority
FI
Finland
Prior art keywords
omaettade
leukotrienantagonister
hydroxial
alkylquinolinsyror
som
Prior art date
Application number
FI914796A
Other languages
English (en)
Other versions
FI914796A0 (fi
FI104897B (fi
Inventor
Michel L Belley
Serge Leger
Patrick Roy
Yi Bin Xiang
Marc Labelle
Daniel Guay
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27082671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI914796(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Publication of FI914796A0 publication Critical patent/FI914796A0/fi
Publication of FI914796L publication Critical patent/FI914796L/fi
Application granted granted Critical
Publication of FI104897B publication Critical patent/FI104897B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI914796A 1990-10-12 1991-10-11 Menetelmä terapeuttisesti käyttökelpoisten 3-[(2-kinolinyyli)etenyyli] fenyyli-1-hydroksialkyylifenyylialkyylitiokarboksyylihappojohdannaisten valmistamiseksi FI104897B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59688790A 1990-10-12 1990-10-12
US59688790 1990-10-12
US74188891A 1991-08-08 1991-08-08
US74188891 1991-08-08

Publications (3)

Publication Number Publication Date
FI914796A0 FI914796A0 (fi) 1991-10-11
FI914796L true FI914796L (fi) 1992-04-13
FI104897B FI104897B (fi) 2000-04-28

Family

ID=27082671

Family Applications (2)

Application Number Title Priority Date Filing Date
FI914796A FI104897B (fi) 1990-10-12 1991-10-11 Menetelmä terapeuttisesti käyttökelpoisten 3-[(2-kinolinyyli)etenyyli] fenyyli-1-hydroksialkyylifenyylialkyylitiokarboksyylihappojohdannaisten valmistamiseksi
FI20000250A FI20000250A7 (fi) 1990-10-12 2000-02-07 Lämpöeristeen asennustuki 3-((2-kinolinyyli)etenyyli)fenyyli-1-hydroksialkyylifenyylialkyylitiokarboksyylihappojohdannaiset

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20000250A FI20000250A7 (fi) 1990-10-12 2000-02-07 Lämpöeristeen asennustuki 3-((2-kinolinyyli)etenyyli)fenyyli-1-hydroksialkyylifenyylialkyylitiokarboksyylihappojohdannaiset

Country Status (26)

Country Link
EP (1) EP0480717B1 (fi)
JP (1) JP2501385B2 (fi)
KR (1) KR100227716B1 (fi)
CN (1) CN1046711C (fi)
AT (1) ATE165088T1 (fi)
CA (1) CA2053209C (fi)
CY (1) CY2094B1 (fi)
CZ (1) CZ281274B6 (fi)
DE (2) DE19875039I2 (fi)
DK (1) DK0480717T3 (fi)
ES (1) ES2114882T3 (fi)
FI (2) FI104897B (fi)
HR (1) HRP930751B1 (fi)
HU (2) HU222344B1 (fi)
IE (1) IE913609A1 (fi)
IL (3) IL99726A (fi)
LU (1) LU90284I2 (fi)
LV (1) LV12187B (fi)
MX (1) MX9101551A (fi)
NL (1) NL990009I2 (fi)
NO (1) NO914004D0 (fi)
NZ (1) NZ240194A (fi)
PT (1) PT99213B (fi)
SI (1) SI9111647B (fi)
SK (1) SK279944B6 (fi)
YU (1) YU48742B (fi)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270324A (en) * 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
CA2111372C (en) * 1992-12-22 2007-01-16 Robert N. Young Diaryl 5,6-fusedheterocyclic acids as leukotriene antagonists
US5472964A (en) * 1992-12-22 1995-12-05 Merck Frosst Canada, Inc. Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
US5438141A (en) * 1993-05-21 1995-08-01 Merck Frosst Canada, Inc. Heteroaryl and haloaryl quinoline derivatives of cyclopropaneacetic acid as leukotriene antagonists
ES2080656B1 (es) * 1993-07-19 1996-10-16 Merck Frosst Canada Inc Acidos de hidroxialquilquinolina fluorados como antagonistas del leucotrieno.
CA2130723C (en) * 1993-09-03 2006-01-31 Wilhelm Quittmann Process for preparing y-mercaptocarboxylic acid derivatives
DE4339724C1 (de) * 1993-11-22 1995-01-19 Siemens Ag Gasarmatur
TW416948B (en) * 1993-12-28 2001-01-01 Merck & Co Inc Process for the preparation of leukotriene antagonists
CA2145735A1 (en) * 1994-04-21 1995-10-22 Paul Hanselmann Process for producing 5-oxaspiro[2.4]heptan-6-one and novel intermediate products obtained therein
US5523477A (en) * 1995-01-23 1996-06-04 Merck & Co., Inc. Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid
US5750539A (en) * 1995-06-07 1998-05-12 Merck Frosst Canada Heteroaryl diol acids as leukotriene antagonists
US5714488A (en) * 1995-10-03 1998-02-03 Abbott Laboratories Bis-heteroarylylmethoxyphenyl ketone derivatives as inhibitors of leukotriene biosynthesis
US5668150A (en) * 1996-07-26 1997-09-16 Abbott Laboratories Non-symmetrical bis-heteroarylmethoxyphenylalkyl carboxylates as inhibitors of leukotriene biosynthesis
FR2751969B1 (fr) * 1996-08-01 1998-12-04 Centre Nat Rech Scient Composes activateurs du canal cftr, et compositions pharmaceutiques les contenant
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US6221880B1 (en) 1998-10-09 2001-04-24 Schering Corporation Composition and method for treating allergic diseases
IT1320162B1 (it) 2000-02-09 2003-11-18 Rotta Research Lab Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico.
CN1318400C (zh) * 2002-02-06 2007-05-30 戴尔玛化学品股份有限公司 制备1－(巯基甲基)－环丙烷乙酸的方法
CA2371048C (en) 2002-02-06 2011-01-04 Delmar Chemicals Inc. Process for the preparation of 1-(mercaptomethyl)-cyclopropaneacetic acid
AU2003209043A1 (en) * 2002-02-07 2003-09-02 Dr. Reddy's Laboratories Ltd. Novel anhydrous amorphous forms of montelukast sodium salt
PT1631550E (pt) 2003-06-06 2012-04-19 Morepen Lab Ltd Um método melhorado para a preparação do ácido montelucaste e do seu sal de sódio na forma amorfa
WO2005040123A1 (en) * 2003-10-10 2005-05-06 Synhton B. V. Solid-state montelukast
US20070225325A1 (en) * 2004-01-28 2007-09-27 Pliva-Istrazivanje I Razvoj D.O.O. Solid Forms of Montelukast Acid
EP1760077A1 (en) * 2004-01-30 2007-03-07 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
MXPA06008584A (es) * 2004-01-30 2007-04-16 Teva Pharma Polimorfos de acido libre de montelukast.
AU2005210236B2 (en) 2004-02-03 2010-09-09 Chemagis Ltd. Stable amorphous forms of montelukast sodium
ES2327762T3 (es) * 2004-04-21 2009-11-03 Teva Pharmaceutical Industries Ltd Procedimiento para preparar montelukast sodico.
US7829716B2 (en) 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
US7501517B2 (en) 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
EP1812394B1 (en) * 2004-07-19 2011-03-02 Matrix Laboratories Ltd Process for the preparation of montelukast and its salts
WO2006008750A2 (en) 2004-07-19 2006-01-26 Matrix Laboratories Ltd Methyl 2-[(3s)-[3-[(2e)-(7-chloro quinolin-2-yl) ethenyl] phenyl]-3-halopropyl] benzoates
EP1781615A1 (en) 2004-07-23 2007-05-09 Pliva Istrazivanje i Razvoj d.o.o. Novel form of a benzenesulfonamide derivative
WO2006021974A1 (en) * 2004-08-23 2006-03-02 Morepen Laboratories Limited A process for synthesizing diol (viii)-an intermediate of montelukast sodium
PL205637B1 (pl) * 2004-10-22 2010-05-31 Inst Farmaceutyczny Sposób wytwarzania kwasu (R,E)-(1-{1-{3-[2-(7-chlorochinolin-2-ylo)etenylo]fenylo}-3-[2-(1-hydroksy-1-metyloetylo)fenylo] propylosulfanylometylo}cyklopropylo)octowego i/lub jego farmaceutycznie dopuszczalnych soli
CA2589936A1 (en) * 2004-11-30 2006-06-08 Medichem S.A. New process for the preparation of a leukotriene antagonist
WO2006131782A1 (en) * 2005-06-07 2006-12-14 Glade Organics Private Limited Process for the manufacture of methyl-2-(3-(2-(7-chloro-2-quinolinyl-ethenyl)-phenyl)-3-oxopropyl) benzoate
EP1904448B1 (en) 2005-07-05 2011-02-02 Teva Pharmaceutical Industries, Ltd. Purification of montelukast
WO2007059325A2 (en) * 2005-11-16 2007-05-24 Teva Pharmaceutical Industries Ltd. Drying methods of montelukast sodium by azeotropic removal of the solvent
AR056815A1 (es) 2005-11-18 2007-10-24 Synthon Bv PROCESO PARA PREPARAR MONTELUKAST, INTERMEDIARIOS DEL MISMO Y SUS SALES DE ADICIoN Y PROCEDIMIENTO DE PURIFICACIoN DE ÉSTOS Y DE MONTELUKAST
EP1968943B1 (en) 2005-12-13 2013-01-23 MSN Laboratories Limited An improved process for the preparation of montelukast and its pharmaceutically acceptable salts
WO2007088545A2 (en) 2006-02-02 2007-08-09 Chemagis Ltd. Novel process for preparing 1-(mercaptomethyl) cyclopropaneacetic acid, a useful intermediate in the preparation of montelukast and salts thereof
IL181607A0 (en) 2006-02-27 2007-07-04 Chemagis Ltd Novel process for preparing montelukast and salts thereof
WO2007101841A2 (en) * 2006-03-06 2007-09-13 Farmaprojects, S. A. Process for preparing a leukotriene antagonist
CN101432267A (zh) 2006-03-17 2009-05-13 斯索恩有限公司 孟鲁司特金刚烷胺盐
EP2004608B1 (en) 2006-04-12 2011-09-14 Glade Organics Private Limited An improved process for the manufacture of montelukast sodium
US20060223999A1 (en) * 2006-05-10 2006-10-05 Chemagis Ltd. Process for preparing montelukast and precursors thereof
GB0614485D0 (en) * 2006-07-21 2006-09-27 Pliva Istrazivanje I Razvoj D Process
EP1886998A1 (en) * 2006-08-09 2008-02-13 Esteve Quimica, S.A. Purification process of montelukast and its amine salts
GB0618703D0 (en) * 2006-09-22 2006-11-01 Almac Sciences Ltd Synthesis of leikotriene compounds
US7700776B2 (en) 2006-10-24 2010-04-20 Formosa Laboratories, Inc. Compounds and preparation for montelukast sodium
US8115004B2 (en) 2006-11-20 2012-02-14 Msn Laboratories Limited Process for pure montelukast sodium through pure intermediates as well as amine salts
US7271268B1 (en) 2006-12-22 2007-09-18 Formosa Laboratories Inc. Process for preparation of [1-(mercaptomethyl)cyclopropyl]acetic acid and related derivatives
EP1958936A1 (en) * 2007-02-14 2008-08-20 Inke, S.A. Process for obtaining montelukast
EP1988079A1 (en) * 2007-04-25 2008-11-05 Lonza Ag Process for the preparation of optically active ethenylphenyl-alcohols
PL205444B1 (pl) 2007-05-02 2010-04-30 Zak & Lstrok Ady Farmaceutyczn Sposób wytwarzania soli sodowej kwasu 1-(((1(R)-(3-(2-(7--chloro-2- chinolinylo)-etenylo)fenylo)-3-(2-(1-hydroksy-1- metyloetylo)fenylo)propylo)sulfanylo)metylo)-cyklopropanooctowego
ES2320077B1 (es) 2007-07-31 2010-02-26 Moehs Iberica, S.L. Proceso de preparacion de un antagonista de leucotrienos y de un intermedio del mismo.
KR101072896B1 (ko) 2007-10-09 2011-10-17 한미홀딩스 주식회사 이온성 액체 매개체를 이용한 몬테루카스트산의 제조 방법
EP2053043A1 (en) 2007-10-26 2009-04-29 Inke, S.A. Crystalline salt of montelukast
DE102007061630B4 (de) 2007-12-20 2013-07-04 Formosa Laboratories, Inc. Neue Verbindungen und Herstellung von Montelukast-Natrium
CN101817818B (zh) * 2008-03-06 2011-10-26 台耀化学股份有限公司 一种用于制备孟鲁司特钠的化合物
WO2009144742A2 (en) 2008-05-26 2009-12-03 Aptuit Laurus Pvt Limited An improved process for preparing montelukast and salts thereof
TR200806298A2 (tr) 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Farmasötik formülasyon
KR101123292B1 (ko) 2008-09-26 2012-03-19 주식회사 엘지생명과학 몬테루카스트 나트륨염의 제조방법
WO2010064109A2 (en) 2008-12-02 2010-06-10 Mayuka Labs Private Limited An improved process for the preparation of montelukast sodium and its intermediates
WO2010107404A1 (en) 2009-03-16 2010-09-23 Mahmut Bilgic Stable pharmaceutical combinations
TW201111392A (en) 2009-06-16 2011-04-01 Schering Corp Novel [3,2-c] heteroaryl steroids as glucocorticoid receptor agonists, compositions and uses thereof
WO2011004298A1 (en) 2009-07-09 2011-01-13 Alembic Limited Montelukast hexamethylenediamine salt and its use for the preparation of montelukast sodium
EP2287154A1 (en) 2009-07-14 2011-02-23 KRKA, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast
CN101638381B (zh) 2009-09-02 2012-08-29 鲁南制药集团股份有限公司 孟鲁司特钠中间体的合成方法
CN102574803A (zh) * 2009-10-09 2012-07-11 帝斯曼知识产权资产管理有限公司 用于制备孟鲁司特的光学活性中间体的合成
AU2009357276A1 (en) 2009-12-23 2012-08-09 Pharmathen S.A. Improved process for the preparation of Montelukast and salts thereof
WO2011121091A1 (en) 2010-03-31 2011-10-06 Krka, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast and novel crystalline form of intermediates therein
KR100990046B1 (ko) * 2010-07-30 2010-10-26 동국제약 주식회사 신규한 몬테루카스트 4-할로 벤질아민염 및 이를 이용한 몬테루카스트 나트륨염의 제조방법
HUP1000425A2 (en) 2010-08-11 2012-03-28 Richter Gedeon Nyrt Process for the production of montelukast sodium
TR201009394A2 (tr) 2010-11-11 2012-06-21 Bi̇lgi̇ç Mahmut Geliştirilmiş montelukast formülasyonları.
TR201009398A2 (tr) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Fiziksel özellikleri geliştirilmiş tablet formülasyonları
US8471030B2 (en) 2010-12-06 2013-06-25 Orochem Technologies Inc. Purification of montelukast using simulated moving bed
EP2502910A1 (en) 2011-03-15 2012-09-26 Laboratorios Lesvi, S.L. Camphorsulfonic salt of a key Montelukast intermediate
CN102690229B (zh) * 2011-03-23 2016-06-08 上海相辉医药科技有限公司 一种孟鲁司特钠的合成及其制备中间体
AU2012320010B2 (en) * 2011-07-26 2017-03-30 Sun Pharma Advanced Research Company Ltd. Quinoline-, quinoxaline or benzothiazole based cysteinyl leukotriene antagonists (LTD4)
WO2013077829A1 (en) 2011-11-21 2013-05-30 Mahmut Bilgic Water-soluble pharmaceutical granules
WO2014118796A1 (en) 2013-01-31 2014-08-07 Melody Healthcare Pvt. Ltd. An in-situ process for the preparation of highly pure montelukast sodium
CN104109122B (zh) * 2013-04-16 2017-03-29 浙江奥翔药业股份有限公司 用于合成孟鲁司特的中间体化合物及其制备方法
CN104370810B (zh) * 2013-08-13 2016-10-05 天津汉瑞药业有限公司 孟鲁司特钠化合物
CN103554017B (zh) * 2013-10-25 2014-12-17 河北序能生物技术有限公司 一种孟鲁司特钠手性中间体的制备方法
CN103936671B (zh) * 2014-05-06 2015-10-28 启东东岳药业有限公司 孟鲁司特钠中间体的制备方法
CN105294556A (zh) * 2014-06-06 2016-02-03 上海迪赛诺化学制药有限公司 一种制备孟鲁司特酸的方法
CN105085391B (zh) * 2015-06-10 2017-08-22 广东默泰同创医药科技有限公司 用作白三烯受体拮抗剂的环丙基不饱和喹啉化合物及应用
CN105363019B (zh) * 2015-12-16 2018-04-24 新乡医学院第一附属医院 一种治疗溶血性贫血的环孢素组合物及其应用
CN108435257A (zh) * 2018-06-08 2018-08-24 福州华博立乐新材料科技有限公司 一种用于合成3-[2-(7-氯-2-喹啉基)乙烯基]苯甲醛的催化剂
CN108530355B (zh) * 2018-06-08 2019-09-10 福州华博立乐新材料科技有限公司 一种3-[2-(7-氯-2-喹啉基)乙烯基]苯甲醛的合成方法
IT201900008340A1 (it) 2019-06-07 2020-12-07 Genetic S P A Sali di montelukast e loro composizioni farmaceutiche

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8801209A1 (es) * 1985-06-18 1988-01-01 Merck Frosst Canada Inc Un procedimiento para la preparacion de quinolinas 2-sustituidas.
IE59889B1 (en) * 1986-02-14 1994-04-20 Merck Frosst Canada Inc 2-substituted quinoline dioic acids
US4851409A (en) * 1986-02-14 1989-07-25 Merck Frosst Canada Inc. 2-substituted quinoline dioic acids and pharmaceutical compositions
JPS62258362A (ja) * 1986-05-02 1987-11-10 Terumo Corp アミド誘導体およびこれを含有する５−リポキシゲナ−ゼ作用阻害剤
EP0271287A3 (en) * 1986-12-11 1990-06-13 Merck Frosst Canada Inc. Quinoline dioic acids and amides
EP0318093A3 (en) * 1987-11-25 1990-12-05 Merck Frosst Canada Inc. Diarylquinoline diacids and their use as medicaments
NZ233752A (en) * 1989-05-24 1993-05-26 Merck Frosst Canada Inc Substituted quinoline derivatives, preparation and pharmaceutical compositions thereof
WO1990015801A1 (en) * 1989-06-22 1990-12-27 Pfizer Inc. Substituted sulfonamides and related compounds in the treatment of asthma, arthritis and related diseases

Also Published As

Publication number Publication date
HK1027473A1 (en) 2001-01-12
NZ240194A (en) 1995-03-28
HU211294A9 (en) 1995-11-28
YU164791A (sh) 1994-04-05
ES2114882T3 (es) 1998-06-16
EP0480717B1 (en) 1998-04-15
HU913217D0 (en) 1992-01-28
SI9111647B (en) 2001-06-30
CN1061407A (zh) 1992-05-27
IL117147A0 (en) 1996-06-18
DE69129257D1 (de) 1998-05-20
DE69129257T2 (de) 1998-11-05
KR920008006A (ko) 1992-05-27
LU90284I2 (fr) 1998-11-03
CY2094B1 (en) 2002-04-05
CA2053209C (en) 1998-12-08
HU222344B1 (hu) 2003-06-28
FI914796A0 (fi) 1991-10-11
JPH05105665A (ja) 1993-04-27
IE913609A1 (en) 1992-04-22
AU8579491A (en) 1992-04-16
NL990009I1 (nl) 1999-06-01
PT99213B (pt) 1999-01-29
LV12187B (en) 1999-02-20
NO914004D0 (no) 1991-10-11
IL99726A (en) 1998-02-22
CZ281274B6 (cs) 1996-08-14
IL99726A0 (en) 1992-08-18
LV12187A (lv) 1998-12-20
AU639610B2 (en) 1993-07-29
FI104897B (fi) 2000-04-28
CA2053209A1 (en) 1992-04-13
HRP930751A2 (en) 1995-06-30
EP0480717A1 (en) 1992-04-15
YU48742B (sh) 1999-09-27
HUT61981A (en) 1993-03-29
SK279944B6 (sk) 1999-06-11
NL990009I2 (nl) 1999-07-01
CS309591A3 (en) 1992-04-15
HRP930751B1 (en) 2000-06-30
FI20000250A7 (fi) 2000-02-07
PT99213A (pt) 1992-09-30
CN1046711C (zh) 1999-11-24
IL117147A (en) 2000-10-31
DE19875039I2 (de) 2003-05-22
DK0480717T3 (da) 1999-02-08
JP2501385B2 (ja) 1996-05-29
MX9101551A (es) 1992-06-05
KR100227716B1 (ko) 1999-11-01
SI9111647A (en) 1997-12-31
ATE165088T1 (de) 1998-05-15

Similar Documents

Publication Publication Date Title
FI914619A7 (fi) Hydroxylfunktionaliserade polyeteraminer som barriaerfoerpackning foer syrekaensliga materialer.
FI914796L (fi) Omaettade hydroxialkylkinolinsyror som leukotrienantagonister.
FI914596L (fi) Biaxialt orienterad polypropylenfolie avsedd som foerpackningsomslag.
FI910993A7 (fi) Hjaelpmedel som foerbaettrar glidegenskaper.
FI931367L (fi) Tvaettmedelskompositioner, som innehaoller polyhydroxifettsyraamider ochen skumfoerstaerkare
FI915357L (fi) Optisk bakskiva som foerbinder kretskort.
FI914004A0 (fi) Epoxifunktionella siloxanhartskopolymerer som loesgoeringsreglerande tillaeggsaemnen.
FI913215L (fi) Additionspolymeriseringskatalysator, som aktiveras medelst oxidering.
FI921182A0 (fi) Velangummi som snabbt hydratiseras.
FI914797A0 (fi) Maettade hydroxialkylkinolinsyror som leukotrienantagonister.
FI920271L (fi) Polyamintioler som straolningsskyddande aemnen.
FI912468L (fi) Oxidantkaensliga och -okaensliga aromatiska estrar som inhibitorer foer humant neutrofilelastas.
FI910572A7 (fi) Regnmaetare med anordning som paovisar tilltaeppning.
FI915568L (fi) Polyamidhartskompositioner foer anvaendning som bindemedel foer laminerande tryckfaergshartser.
FI910425L (fi) Di- och tetrafluoranaloger av skvalen som skvalenepoxidas-inhibitorer.
FI914201L (fi) Anvaendning av staerkelseblandningar som puddingstaerkelse.
FI923367L (fi) Molekyler med antikroppkombinations- staellen som katalyserar hydrolysreaktioner.
FI913225A7 (fi) Vattenstraoledrift foer fartyg som avsetts att anvaendas i grunda vatten.
FI892214L (fi) Kopparlegering foer anvaendning som motstaondssvetselektrod.
FI895483A0 (fi) Som slaglod anvaendbara kopparblandningar.
FI911720L (fi) Anvaendning av makrocykliska foereningar som komponenter foer ferroelektriska vaetskekristallblandningar.
FI912287L (fi) Anvaendning av heminnehaollande proteiner som stabilisatorer foer enzymmaerkta immunreaktanter.
FI914795L (fi) Hydroxialkylkinolinetersyror som leukotrienantagonister.
FI932654L (fi) Hydroxamsyraderivat, som hindrar lipoxigenas
FI932873A7 (fi) D-homo-(16-en)-11b-aryl-4-estrener, foerfarande foer deras framstaellningoch deras anvaendning som laekemedel

Legal Events

Date Code Title Description
HC Name/ company changed in application

Owner name: MERCK FROSST CANADA & CO.

PC Transfer of assignment of patent

Owner name: MERCK FROSST CANADA LTD.

Free format text: MERCK FROSST CANADA LTD.

MA Patent expired